A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system
Abstract Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccine...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01064-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595011848372224 |
|---|---|
| author | Girmay Desalegn Charlotte Abrahamson K. Ross Turbyfill Lucy Pill-Pepe Leslie Bautista Chitradevi S. Tamilselvi Dylan Dunn Neeraj Kapoor Barbara Sullinger Matheo Herrera Edwin V. Oaks Jeff Fairman Marcela F. Pasetti |
| author_facet | Girmay Desalegn Charlotte Abrahamson K. Ross Turbyfill Lucy Pill-Pepe Leslie Bautista Chitradevi S. Tamilselvi Dylan Dunn Neeraj Kapoor Barbara Sullinger Matheo Herrera Edwin V. Oaks Jeff Fairman Marcela F. Pasetti |
| author_sort | Girmay Desalegn |
| collection | DOAJ |
| description | Abstract Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccines based on Shigella conserved proteins are sought for their simplicity and capacity to prevent disease caused by multiple serotypes. We previously reported the broad protective capacity of VirGα, a conserved surface-exposed domain of Shigella virulence factor. Seeking to refine the vaccine antigenic target and achieve scalable manufacturing compatible with Good Manufacturing Practices, we mapped linear B-cell epitopes spanning the entire VirG protein sequence by probing the immune reactivity of 10-mer peptides (overlapping 4–8 aa) with sera from Shigella-infected rhesus monkeys. The surface-exposed VirG53 – 353 subregion of the passenger α-domain demonstrated the highest and strongest immunoreactivity. VirG53 – 353 was produced efficiently at a large scale (>150 mg/L) using cell-free protein synthesis. When administered to mice intramuscularly, VirG53 – 353 elicited robust antibody responses and conferred high levels of protection against the three most prevalent Shigella serotypes (S. flexneri 2a, 3a, and S. sonnei). VirG53 – 353 evoked the production of Th2-type cytokines by spleen cells from vaccinated mice. A new universal Shigella vaccine based on VirG53 – 353 meets the World Health Organization’s preferred product specifications. The target antigen refinement and production improvement described here will facilitate the first-in-human studies. |
| format | Article |
| id | doaj-art-eba9356b62c74cf3b010037c54239781 |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-eba9356b62c74cf3b010037c542397812025-01-19T12:09:17ZengNature Portfolionpj Vaccines2059-01052025-01-0110111010.1038/s41541-025-01064-6A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free systemGirmay Desalegn0Charlotte Abrahamson1K. Ross Turbyfill2Lucy Pill-Pepe3Leslie Bautista4Chitradevi S. Tamilselvi5Dylan Dunn6Neeraj Kapoor7Barbara Sullinger8Matheo Herrera9Edwin V. Oaks10Jeff Fairman11Marcela F. Pasetti12Center for Vaccine Development and Global Health, University of Maryland School of MedicineVaxcyte Inc.Department of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of ResearchVaxcyte Inc.Vaxcyte Inc.Center for Vaccine Development and Global Health, University of Maryland School of MedicineCenter for Vaccine Development and Global Health, University of Maryland School of MedicineVaxcyte Inc.Vaxcyte Inc.Vaxcyte Inc.Department of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of ResearchVaxcyte Inc.Center for Vaccine Development and Global Health, University of Maryland School of MedicineAbstract Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccines based on Shigella conserved proteins are sought for their simplicity and capacity to prevent disease caused by multiple serotypes. We previously reported the broad protective capacity of VirGα, a conserved surface-exposed domain of Shigella virulence factor. Seeking to refine the vaccine antigenic target and achieve scalable manufacturing compatible with Good Manufacturing Practices, we mapped linear B-cell epitopes spanning the entire VirG protein sequence by probing the immune reactivity of 10-mer peptides (overlapping 4–8 aa) with sera from Shigella-infected rhesus monkeys. The surface-exposed VirG53 – 353 subregion of the passenger α-domain demonstrated the highest and strongest immunoreactivity. VirG53 – 353 was produced efficiently at a large scale (>150 mg/L) using cell-free protein synthesis. When administered to mice intramuscularly, VirG53 – 353 elicited robust antibody responses and conferred high levels of protection against the three most prevalent Shigella serotypes (S. flexneri 2a, 3a, and S. sonnei). VirG53 – 353 evoked the production of Th2-type cytokines by spleen cells from vaccinated mice. A new universal Shigella vaccine based on VirG53 – 353 meets the World Health Organization’s preferred product specifications. The target antigen refinement and production improvement described here will facilitate the first-in-human studies.https://doi.org/10.1038/s41541-025-01064-6 |
| spellingShingle | Girmay Desalegn Charlotte Abrahamson K. Ross Turbyfill Lucy Pill-Pepe Leslie Bautista Chitradevi S. Tamilselvi Dylan Dunn Neeraj Kapoor Barbara Sullinger Matheo Herrera Edwin V. Oaks Jeff Fairman Marcela F. Pasetti A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system npj Vaccines |
| title | A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system |
| title_full | A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system |
| title_fullStr | A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system |
| title_full_unstemmed | A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system |
| title_short | A broad spectrum Shigella vaccine based on VirG53 – 353 multiepitope region produced in a cell-free system |
| title_sort | broad spectrum shigella vaccine based on virg53 353 multiepitope region produced in a cell free system |
| url | https://doi.org/10.1038/s41541-025-01064-6 |
| work_keys_str_mv | AT girmaydesalegn abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT charlotteabrahamson abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT krossturbyfill abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT lucypillpepe abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT lesliebautista abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT chitradevistamilselvi abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT dylandunn abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT neerajkapoor abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT barbarasullinger abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT matheoherrera abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT edwinvoaks abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT jefffairman abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT marcelafpasetti abroadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT girmaydesalegn broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT charlotteabrahamson broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT krossturbyfill broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT lucypillpepe broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT lesliebautista broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT chitradevistamilselvi broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT dylandunn broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT neerajkapoor broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT barbarasullinger broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT matheoherrera broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT edwinvoaks broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT jefffairman broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem AT marcelafpasetti broadspectrumshigellavaccinebasedonvirg53353multiepitoperegionproducedinacellfreesystem |